Similarly, lucanthone inhibits DNA repair activity of APE1 without affecting the redox function (39) and is in phase II clinical trials for treatment of brain metastases secondary to non-small cell lung cancer (NCT02014545). This evidence concerns the gene APEX1 and non-small cell lung carcinoma.